Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gemma Currie

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Placenta|March 28, 2016
Placental expression of the angiogenic placental growth factor is stimulated by both aldosterone and simulated starvationNicole Eisele, Christiane Albrecht, Hiten D Mistry, et al.
NEJM Evidence|June 21, 2024
Effect of Fenofibrate on Progression of Diabetic RetinopathyDavid Preiss, Jennifer Logue, Emily Sammons, et al.
Diabetes, Obesity & Metabolism|October 29, 2024
Effect of spironolactone wash-out on albuminuria after long-term treatment in individuals with type 2 diabetes and high risk of kidney disease-An observational follow-up of the PRIORITY studyVictor Wasehuus, Viktor Rotbain Curovic, Nete Tofte, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|July 3, 2025
Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: An economic evaluation based on data from the LENS trialGraham Scotland, Mekazin Tsehaye, Caroline Styles, et al.
BMJ Open|March 4, 2016
Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trialMorten Lindhardt, Frederik Persson, Gemma Currie, et al.
Health Technology Assessment (Winchester, England)|May 12, 2026
Fenofibrate and progression of retinopathy in adults with diabetes: the randomised placebo-controlled LENS trialDavid Preiss, Jennifer Logue, Emily Sammons, et al.
BMC Nephrology|September 10, 2016
Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysisGemma Currie, Alison H M Taylor, Toshiro Fujita, et al.
The Lancet. Diabetes & Endocrinology|March 6, 2020
Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trialNete Tofte, Morten Lindhardt, Katarina Adamova, et al.
Journal of Diabetes and Its Complications|February 25, 2023
Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trialViktor Rotbain Curovic, Nete Tofte, Morten Lindhardt, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Placenta|March 28, 2016
Placental expression of the angiogenic placental growth factor is stimulated by both aldosterone and simulated starvationNicole Eisele, Christiane Albrecht, Hiten D Mistry, et al.
NEJM Evidence|June 21, 2024
Effect of Fenofibrate on Progression of Diabetic RetinopathyDavid Preiss, Jennifer Logue, Emily Sammons, et al.
Diabetes, Obesity & Metabolism|October 29, 2024
Effect of spironolactone wash-out on albuminuria after long-term treatment in individuals with type 2 diabetes and high risk of kidney disease-An observational follow-up of the PRIORITY studyVictor Wasehuus, Viktor Rotbain Curovic, Nete Tofte, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|July 3, 2025
Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: An economic evaluation based on data from the LENS trialGraham Scotland, Mekazin Tsehaye, Caroline Styles, et al.
BMJ Open|March 4, 2016
Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trialMorten Lindhardt, Frederik Persson, Gemma Currie, et al.
Health Technology Assessment (Winchester, England)|May 12, 2026
Fenofibrate and progression of retinopathy in adults with diabetes: the randomised placebo-controlled LENS trialDavid Preiss, Jennifer Logue, Emily Sammons, et al.
BMC Nephrology|September 10, 2016
Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysisGemma Currie, Alison H M Taylor, Toshiro Fujita, et al.
The Lancet. Diabetes & Endocrinology|March 6, 2020
Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trialNete Tofte, Morten Lindhardt, Katarina Adamova, et al.
Journal of Diabetes and Its Complications|February 25, 2023
Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trialViktor Rotbain Curovic, Nete Tofte, Morten Lindhardt, et al.
Pageof 3